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Aberrant JNK signaling can result in two main forms of disease in humans: 1) 
neurological, coronary, hepatobiliary, and respiratory diseases and 2) autoimmune, 
inflammatory, and cancer conditions. Enantiomers of the lignan zuonin A, (-)-zuonin A 
and (+)-zuonin A, have been shown to bind to JNK isoforms with similar affinity and 
disrupt protein-protein interactions at JNK’s D-recruitment site, making them a good 
candidate for specific non-ATP competitive inhibitors. However, (-)-zuonin A inhibits 
80% of JNK catalyzed reactions at saturating levels, while (+)-zuonin A only inhibits 
15%. Molecular docking and molecular dynamics simulations were performed to gain a 
better understanding of how these inhibitors interact JNK. The results of this study 
provide an alternative binding mode for (-)-zuonin A, compared to one proposed in a 
previous study, that shows (-)-zuonin A interacting with JNK via an induced fit 
mechanism by forming a larger pocket for itself near the highly conserved φA-X-φB 
recognition site, a dynamic move not seen in (+)-zuonin A simulations, and may help 
explain their different inhibition patterns.  
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Chapter 1:  Introduction 
MITOGEN ACTIVATED PROTEIN (MAP) KINASES 
Mitogen Activated Protein (MAP) kinases are a class of serine/threonine specific 
protein kinases that are highly conserved in eukaryotic organisms. These enzymes are 
most commonly members of a three tiered signal transduction cascade which uses a 
series of phosphorylation events to help relay “messages” from external stimuli to 
intracellular targets in order to elicit a desired cellular response.[1] 
 
 
Figure 1: Overview of a mammalian MAP kinase cascade[2] 
There are three main MAPK pathways in mammals, ERK1/2 (Extracellular-
Signal-Regulated Kinases), ERK5, and p38/JNK (c-Jun N-terminal Kinases). ERK1/2 
and ERK5 pathways are both activated by the binding of mitogens and growth factors at 
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cell surface receptors and regulate cellular proliferation, division, and differentiation. The 
p38/JNK pathway is activated in response to environmental stresses, such as 
hyperosmosis, oxidative stress, UV radiation and inflammatory cytokines, and can result 
in apoptosis, inflammation, cell cycle arrest, or cellular differentiation. Unfortunately, 
miscues in MAPK signaling can result in chronic diseases such as cancer, obesity, type-2 
diabetes, inflammation and Alzheimer’s disease.[3-6] 
 
 
Figure 2: Diseases linked to aberrant JNK signalling 
MAP kinases have the canonical core structure seen in other protein kinases. 
These features include two domains connected by a hinge region which allows for minor 
flexibility, an ATP binding pocket and substrate recognition site at the domain interface 
which help catalyze the transfer of ATP’s gamma phosphate to the substrate’s hydroxyl 
group, and an activation loop located in close proximity to the active site which 
determines the activation state of the kinase. The activation loop contains two 
phosphorylation sites in the form of a T-X-Y motif for MAP kinases.[1] 
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An interesting feature of MAP kinases is their use of docking regions to recruit, 
orient, and discriminate between activators, regulators, and substrates. The MAPK D-
recruitment site (DRS) was of particular interest in this study. The DRS targets proteins 
and peptides containing a D-site motif via a negatively charged common docking (CD) 
domain and a hydrophobic groove. Successful binding to this region helps align the two 
proteins and increases the likelihood for the desired catalytic reaction.[7] 
 
 
Figure 3: General MAPK structure with consensus D-site. 
The positively charged amino acids, denoted as θ in figure 3, of the D-site interact 
with the negatively charged amino acids of the CD domain. In addition, the highly 
conserved hydrophobic residues, φL,A,B, form van der Waal’s contacts with pockets 
formed along the hydrophobic groove.[7] 
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C-JUN N-TERMINAL KINASES (JNKS) AND THEIR ROLE IN DISEASE 
JNKs are members of the MAP kinase family and play an integral role in 
eukaryotic cellular stress response mechanisms. JNK is encoded by genes Jnk1, Jnk2, and 
Jnk3 and have 10 different splice variants. While JNK1 and JNK2 are ubiquitously 
expressed throughout the body, JNK3 is predominately localized to the brain, testis and 
heart. All isoforms are activated by dual phosphorylation of the Thr-Pro-Tyr motif 
located on the activation loop of the enzyme. The tyrosine and threonine residues are 
phosphorylated by upstream kinases MKK4 and MKK7 respectively.[3] 
 
Figure 4: a) Anatomy of JNK1 b) JIP1 peptide bound to JNK1’s D-recruitment site 
Aberrant JNK signaling can result in two main forms of disease in humans: 1) 
neurological, coronary, hepatobiliary, and respiratory diseases and 2) autoimmune, 
inflammatory, and cancer conditions. 
JNKs play a vital role proper in brain/neurological development. Single knockout 
studies of any JNK isoform, in addition to Jnk1/Jnk3 and Jnk2/Jnk3 double knockouts, 
had no deleterious effects on mouse development. However, the Jnk1/Jnk2 double 
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knockout resulted in early embryonic termination due to unregulated apoptosis of 
neuronal cells in the brain. This suggests that JNK1 and JNK2 may have some redundant 
functions.  
Contrary to their similar function in brain development, JNK1 and JNK2 appear 
to have separate roles in fibroblast proliferation and the progression of certain forms of 
cancer. Studies have shown that upregulation of JNK1 increases c-Jun phosphorylation 
and activation resulting in cellular proliferation, while the inverse is true for JNK2.  
The diverse roles of JNKs in human pathogenesis make it a desirable drug target, 
however, finding the appropriate specificity amongst other kinases, let alone the JNK 
isoforms, has been a challenge.[4] 
INHIBITION OF JNKS AND ZUONIN A 
Two main strategies have been employed for the development of JNK inhibitors.   
ATP competitive inhibitors target the ATP binding pocket, as the name suggests, while 
non-ATP competitive inhibitors bind to the D-recruitment site and disrupt target substrate 
binding. One successful ATP competitive inhibitor, SP600125, has been proven to be 
effective at inhibiting JNK in both cell culture as well as mouse models. However, 
targeting the ATP binding site comes at the cost of reduced specificity due to the 
conserved nature and abundance of ATP binding pockets.[8] In addition, ATP 
competitive inhibitors must compete with high concentrations of intracellular ATP, 
which vary from 1-10 mM. 
For these reasons, there has been a push to develop non-ATP competitive 
inhibitors. A JNK interacting protein-1 (JIP1) peptide fragment known to interact with 
the JNK D-recruitment site was able to selectively inhibit JNK over other similar MAP 
kinases such as ERK2 and p38, figure 4b. Unfortunately, the large number of degrees of 
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freedom of the peptide backbone and issues with bioavailability make peptide drugs a 
somewhat undesirable lead compound. To combat this issue, a library of small molecules 
was screened to reveal compounds capable of disrupting the JIP1 and JNK1 interaction. 
One potential lead discovered in this screen was BI-78D3. BI-78D3 confirmed that the 
concept of targeting the DRS using small molecules could potentially be effective by 
inhibiting the phosphorylation of JNK1 substrates in a dose dependent manner.[9] 
In order to expand on the number of non-ATP competitive inhibitor scaffolds, a 
virtual screen was performed to compare BI-78D3 to other compounds based on three-
dimensional shape and electrostatic similarities. One compound of interest isolated from 
this study was the lignan (-)-zuonin A, figure 5, which has a 100-fold greater selectivity 
toward inhibiting JNK–protein interactions over ERK2 and p38 MAPKα.[10] 
 
 
Figure 5: Chemical structure of zuonin A enantiomers 
An interesting observation regarding (-)-zuonin A and its enantiomer, (+)-zuonin 
A, was that both were equally as effective at displacing pepJIP1 from JNK1 (IC50 of ~2.6 
± 0.2 μM), however, at saturating concentrations, (-)-zuonin A inhibited 80% the 
maximal phosphorylation reaction, whereas (+)-zuonin A only inhibited 15%. This 
information suggests that the two zuonin A enantiomers must interact with JNK1 in 
different manners and is the motivation for the subject matter of this thesis.[11] 
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COMPUTER AIDED DRUG DESIGN 
Statistics from 2000 through 2007 show that it takes between 11.4 to 13.5 years 
for a company to take a small molecule drug to market at an approximate cost of $1.8 
billion.[12] These economic challenges and vast improvements in computational 
technology have sparked innovation in the field of computer aided drug design (CADD) 
with the goal of increasing search efficiency while decreasing the necessary costs. 
Virtual screening has experienced wide spread use in the field of medicinal 
chemistry due to their ability to quickly screen large libraries of compounds at very little 
cost. One such ligand-based screen is a ligand-ligand similarity search which compares a 
known bioactive ligand to a library of compounds and ranks them according to a defined 
property such as shape, electrostatic profile, and/or biological activity. A de novo search 
for ligands can also be performed using molecular docking. This process requires a model 
of the target structure which can be obtained by experiment (x-ray crystallography/NMR 
data) or generated using homology modeling software. In this method, ligands are 
allowed to move freely and change conformations in an attempt to best fit the inverse of a 
user defined pocket. The generated configurations are known as poses. Each pose is 
scored and ranked using a scoring function which is usually an over-simplified empirical 
force field. These scoring functions rely on empirical data sets of known binding 
affinities with solved structures to derive contribution weights for lipophilic effects, 
hydrogen bonds, and rotatable bonds. 
Unfortunately, molecular docking has several inherent flaws. Since target proteins 
have little to no flexibility, it gives an unrealistic landscape for the ligand to dock into 
and becomes a larger issue as a protein becomes more dynamic. Most docking programs 
also give a “binding free energy” for each snapshot, when in actuality it is ensemble-
averaged thermodynamic quantity including vibrational, rotational, and conformational 
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contributions. Also, since scoring function parameters are usually optimized to a certain 
set of known substrate-ligand interactions which can result in an unwanted bias toward 
interactions not included in the training set. Lastly, molecular docking scoring functions 
do a poor job accounting for entropy and solvent effects that can be critical for substrate 
ligand binding. Although the success rate of molecular docking can be increased by using 
multiple scoring functions and using consensus scores, there is much left to be desired. 
Physics based molecular mechanics force fields in conjunction with molecular 
dynamics (MD) or Monte Carlo (MC) simulations have been implemented in the drug 
discovery process to ameliorate many of the issues seen in molecular docking 
experiments. These simulations allow for the inclusion of explicit water molecules, 
movement of all atoms in the system, including protein and solvent, and more rigorous 
interaction energies calculated from detailed molecular mechanics force fields. A 
molecular mechanics force field is the summation of all the bonded and non-bonded 
forces experienced by a particular atom and has the general form seen in following 
equation. 
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Eq. 1: Generalized force field equation 
The bonded terms include bond lengths and bond angles, which are both 
represented mathematically as springs, and dihedral angles, which are modeled as 
periodic waves. The non-bonded van der Waals forces are approximated using a 
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Lennard-Jones potential and long range electrostatic interactions are taken into account 
using Coulomb’s Law. 
Once the potential energy of an atom at given coordinates, r, has been determined, 
it’s possible to calculate the forces, F, acting on each atom by taking the gradient of the 
potential energy at time, i. 
 (  )     (  ) 
Eq. 2 
Newton’s second law of motion can be applied to determine the acceleration, A, 
of that atom at that given moment if the forces and mass of the atom are known.  
 (  )   (  )   
Eq. 3 
Using a small time step, usually on the order of 1 to 2 femtoseconds for atomic 
models, one can determine the new position, of each atom after each step. 
             
 
 ⁄    
  
Eq. 4 
The potential energy is calculated once again and the process is then repeated 
until the user obtains a desired sample size. One benefit to using molecular dynamics 
simulations is that the resulting trajectory follows a Boltzmann distribution and can thus 
be used to calculate fundamental properties of the system by straight averaging. 
Once a trajectory of a protein-ligand interaction is obtained, the Molecular 
Mechanics-Generalized Born (Poisson-Boltzmann) Surface Area, or MM-GB(PB)SA, 
implicit solvent method can be used to calculate the binding free energy of the ligand 




Figure 6: Thermodynamic cycle exploited to calculate solvated binding free energy 
(ΔG°Binding,Solv) using the MM-GBSA algorithm, where the grey JNK1 
enzyme binds a zuonin A enantiomer to form a complex both in vacuum and 
solvent 
Solvation free energies, ΔGSolv, are the sum of the solvation energy of the polar 
contributions, ΔGSolv,polar, as determined using either the GB or PB method, and the 
solvation energy of the non-polar portion, ΔGSolv,nonpolar, was calculated using the surface 
area of the molecule. 
                                    
Eq. 5 
 The binding free energy in a vacuum, ΔGBinding,Vac, is simply the sum of the 
change in enthalpy, ΔUMM,Vac, and entropy, TΔS, terms going from their respective 




                         
Eq. 6 
Thus, the solvated binding free energy can be approximated by combining the 
previous equations to get: 
                                     
Eq. 7 
Where ΔUMM,Vac is calculated using the molecular mechanics force field, ΔGGB is 
the electrostatic (polar) solvation energy calculated using the Generalized-Born method, 
ΔGSA is the nonpolar contributions to solvation energy based on the exposed surface area, 
and ΔS is the change in entropy which can be estimated using normal mode analysis and 
other methods. 
The use of MD simulations ultimately gives the user a more accurate binding free 
energy by taking the ensemble average of a large number of potential conformations. In 
addition, each trajectory can be viewed using visualization software like VMD or 





Chapter 2:  Experimental Design 
IN SILICO REPRESENTATIONS OF JNK1 AND ZUONIN A  
The dephosphorylated JNK1 structure used was previously generated by adding 
back missing amino acid residues to the crystal structure of the JNK1-JIP1 peptide 
complex (PDB ID: 1UKH)[8] using the homology software Modeler9v5[6]. Missing 
residues were far enough away from the proposed binding sites that they did not affect 
the initial docking experiments. Zuonin enantiomers were drawn using MarvinSketch and 
converted to 3D coordinates. 
 
Figure 7: a) Crystal structure of JNK1 with missing residues (PDBID: 1UKH) b) Missing 
residues replaced in orange using Modeler9v5 with Thr183 & Tyr185 
emphasized. 
MOLECULAR DOCKING 
Docking experiments were performed using Genetic Optimisation for Ligand 
Docking (GOLD) software provided by the Cambridge Crystallographic Data Centre 
(CCDC).[13] Both zuonin A enantiomers were docked 100 times into 10 different 
regions along the JNK-JIP1 interface yielding 1000 potential poses. The regions were 
defined as all JNK atoms within a 16Å radius of each JIP1 α-carbon to accommodate the 
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approximate width of zuonin (~14Å). Each docking began with an initial population of 
200 members divided onto 5 islands. Crossover events were controlled using a niche size 
of 2 and a selection pressure of 1.1. The quality of fit for each pose was calculated using 
the Chemscore fitness function with the default parameters supplied by CCDC. 
All docking poses were combined and clustered based on their RMSD calculated 
using GoldMine.[13] The highest scoring pose in each cluster was selected for the 
subsequent molecular dynamics simulation. 
MOLECULAR DYNAMICS SIMULATIONS 
Gaussian09 quantum mechanics software was used to optimize the 3D structure 
of zuonin and calculate accurate atomic charges.[14] The electrostatic potential for each 
atom was determined using the Merz-Singh-Kollman scheme.[15, 16]  All calculations 
were performed using the Hartree-Fock/6-31G* basis set. The optimized structures were 
converted to Amber parameter and coordinate files using the antechamber and LEaP 
modules of Amber12 and the General Amber Force Field (GAFF).[17] 
The topology and coordinate files for the zuonin-JNK1 complexes were created 
with LEaP using the ff99SB force field in conjunction with the previously generated 
parameter, coordinate and library files for zuonin. A set of topology and coordinate files 
were also created for the solvated system which consisted of a truncated octahedral 
TIP3P water box that extended 8Å from the enzyme's surface and added 4 Na+ 
counterions to balance the overall charge. 
All minimization and MD equilibration steps were executed using the Sander 
module of Amber12 while production runs were performed using the PMEMD (Particle 
Mesh Ewald Molecular Dynamics) module. To remove any potential bad contacts, each 
system was minimized while holding the peptide backbone rigid until it converged to less 
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than 0.001 kcal/mole*Å. The steepest descent algorithm was used for the first 500 steps 
followed by 500 cycles of the conjugate gradient method. 
The system was equilibrated using a two-step process. First, a 200ps NVT 
simulation was performed using a 2.0 fs integration timestep. The system was heated 
from 0K to 300K during the first 80ps and held constant for the remainder of the 
simulation. A second 1ns NPT equilibration step was executed at 1bar to equilibrate the 
size of the system. In both steps, all backbone atoms present in the original crystal 
structure were restrained while all other atoms were allowed to move freely. 
An 8ns trajectory was acquired for each production run. A total of 28 simulation 
runs were performed for both zuonin A enantiomers at various poses (14 for (-)-zuonin A 
and 14 for (+)-zuonin A). The conditions of this step were the same as the second 
equilibration step except all backbone restraints were removed. 
For all MD simulations a Langevin thermostat was used to regulate the system's 
temperature, all covalent hydrogen bond lengths were constrained using the SHAKE 
algorithm, and a 10Å cutoff was used for van der Waals interactions and Particle-Mesh-
Ewald (PME)[18] for electrostatics. 
BINDING FREE ENERGY VIA MM-GBSA 
The Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) method 
was used to calculate the free energy difference between the bound and unbound states. 
MD trajectories from each production run were processed with the MMPBSA.py module 
of Amber12. Solvation energies were calculated using the Hawkins, Cramer, Truhlar 
pairwise generalized Born model representation of implicit solvent. Due to the time 
consuming nature and unreliable methods currently available for estimating entropic 
contributions, it was assumed that the effect of entropy on binding was similar across all 
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Chapter 3: Results and Discussion 
MOLECULAR DOCKING 
Molecular docking results of both zuonin enantiomers docked to the pepJIP1 
binding site of JNK1 tended to cluster into two pockets that are critical for JIP1 peptide 
binding; the highly conserved φA-X-φB recognition site, Φhyd, and another hydrophobic 
pocket usually occupied by Pro158 of pepJIP1 (φA-2) or “site 2”, denoted as S2, as 
described by Kaoud et al., figure 8.[10] RMSD cluster analysis revealed 14 unique 
binding poses for each zuonin A enantiomer yielding 28 total configurations.  
Of the 14 poses generated for (+)-zuonin A, 5 were bound to the Φhyd region with 
the tetrahydrofuran (THF) located directly in the φA-X-φB recognition site. The 
remaining 9 poses were localized to the S2 region. Zuonin A’s central THF ring and 
methyl groups occupied the same pocket as Pro158 of JIP1 in 7 of these poses while the 
remaining two shifted away from Arg127 and occupied the Pro158 pocket with a 1,3-
benzodioxole ring. 
Like (+)-zuonin A, the majority of (-)-zuonin A molecules bound to the S2 site, 8 
of 11, had the central THF ring and methyl substitutions in the vicinity of the proline 
pocket while the remaining three also occupied the proline pocket with a 1,3-
benzodioxole ring. However, unlike (+)-zuonin A, all three poses in the Φhyd region had 
an elongated configuration with one 1,3-benzodioxole ring occupying the φA-X-φB 
recognition site with the rest of the molecule extended away from Arg127, forming 
interactions with a shallow groove located above the pocket. 
On the whole, docking poses that aggregated in the S2 pocket scored more 
favorably than those that bound to Φhyd, table 1. Decomposition of the contributions for 
each ligand revealed that conformations bound to S2 had a greater contribution from 
lipophilic interactions than those bound to the Φhyd. The S2 pocket is deeper in the crystal 
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structure than that of Φhyd, thus enhancing its ability to shield zuonin A’s hydrophobic 
core. 
Pose 20 had the highest chemscore (26.7) for (+)-zuonin A. This pose was bound 
to the S2 site and had the THF ring in close proximity to the proline site with both methyl 
groups extended into the pocket. The pose appears to be further stabilized by the stacking 
of one of its 1,3-benzodioxole rings between the groove formed by Arg127, Cys163, and 
Asp162. This pose was quite similar to a (-)-zuonin A binding mode proposed by Kaoud 
et al.[11] 
The highest scoring pose for (-)-zuonin A was pose 10, table 1. This pose also 
interacted with the S2 site and had a chemscore of 25.7. Unlike (+)-zuonin A, pose 10 
buried one of its 1,3-benzodioxole rings into the proline pocket and extended itself in the 
opposite direction of Arg127 making contacts in a shallow groove in the direction of the 
CD domain. 
 
Figure 8: Docking Results for a) (-)-zuonin A and b) (+)-zuonin A. The φA-X-φB 
recognition site and Site 2 are denoted as Φhyd and S2 respectively. The 




Table 1: JNK1/Zuonin A enantiomers docking results. 
 
DG=Estimated binding free energy; S(hbond), S(metal), S(lipo) = hydrogen bond, metal, lipophilic contributions; 
H(rot) = rotatable bond contribution; DE(clash) = vdW overlap; DE(int) = internal strain; Region = docking region 
Pose # ChemScore DG S(hbond) S(metal) S(lipo) H(rot) DE(clash) DE(int) Region
10 25.7 -26.3 1.29 0 169 1.28 0.42 0.15 S2
11 24.7 -25.3 0.74 0 176 1.28 0.54 0.02 S2
12 24.6 -24.9 0.67 0 175 1.28 0.34 0.03 S2
27 24.2 -24.6 0.00 0 191 1.28 0.23 0.19 S2
14 24.0 -24.5 0.46 0 178 1.28 0.22 0.29 S2
9 24.0 -24.8 0.93 0 167 1.28 0.68 0.15 S2
31 23.9 -24.5 0.00 0 190 1.28 0.56 0.05 S2
24 23.8 -24.1 0.93 0 160 1.28 0.18 0.09 S2
33 23.6 -25.7 1.80 0 149 1.28 1.83 0.24 S2
40 23.4 -24.2 0.62 0 170 1.28 0.44 0.32 S2
37 23.2 -23.6 0.94 0 156 1.28 0.31 0.09 S2
43 19.6 -20.3 0.99 0 126 1.28 0.53 0.14 Φhyd
44 19.6 -20.0 0.99 0 124 1.28 0.28 0.14 Φhyd
45 18.7 -19.3 0.00 0 146 1.28 0.52 0.11 Φhyd
Pose # ChemScore DG S(hbond) S(metal) S(lipo) H(rot) DE(clash) DE(int) Region
20 26.7 -27.2 1.20 0 179 1.28 0.42 0.08 S2
1 25.5 -25.7 0.94 0 173 1.28 0.14 0.04 S2
7 25.4 -25.6 0.92 0 174 1.28 0.18 0.00 S2
31 24.7 -25.7 1.35 0 162 1.28 0.31 0.69 S2
19 24.5 -24.7 0.95 0 165 1.28 0.19 0.01 S2
22 24.3 -24.5 0.90 0 165 1.28 0.26 0.01 S2
15 24.2 -24.5 0.90 0 165 1.28 0.23 0.08 S2
34 23.8 -24.0 0.95 0 159 1.28 0.19 0.09 S2
4 23.6 -23.9 0.00 0 185 1.28 0.18 0.04 S2
41 22.3 -22.9 0.00 0 177 1.28 0.52 0.05 Φhyd
46 22.2 -22.7 0.01 0 175 1.28 0.18 0.36 Φhyd
32 21.5 -21.7 0.00 0 167 1.28 0.26 0.04 Φhyd
39 21.3 -21.9 0.00 0 168 1.28 0.12 0.48 Φhyd





MOLECULAR DYNAMICS SIMULATIONS & BINDING FREE ENERGY VIA MM-GBSA 
In stark contrast to the docking scores, 8 ns molecular dynamics simulations that 
used the 14 unique docking configurations for each zuonin A enantiomer as a starting 
point revealed that zuonin A molecules bound to the φA-X-φB recognition site, Φhyd, had 
a lower binding free energy than those bound to the φA-2 hydrophobic pocket, S2, for 
both enantiomers, table 2. 
Table 2: Zuonin A/JNK1 binding free energy estimates via MM-GBSA after 8ns MD 
simulations. All values are in kcal/mol. 
 
ΔGbinding, ΔGgas, ΔGsolv = solvated binding free energy, binding free energy in vacuum, solvation free energy; 
BOND, ANGLE, DIHED = bond length, bond angle, dihedral angle energies; VDWAALS, EEL = vdW interactions 
and electrostatics energies; EGB, ESURF = polar and nonpolar solvation energies 
Pose # ΔG binding ΔG gas ΔG solv BOND ANGLE DIHED VDWAALS EEL EGB ESURF Region
43 -26.48 -38.30 11.82 0.00 0.00 0.00 -32.93 -5.37 15.69 -3.87 Φhyd
45 -22.22 -30.77 8.55 0.00 0.00 0.00 -28.25 -2.52 12.19 -3.64 Φhyd
44 -16.72 -22.81 6.09 0.00 0.00 0.00 -23.20 0.40 8.92 -2.83 Φhyd
24 -16.21 -27.16 10.94 0.00 0.00 0.00 -22.48 -4.68 13.61 -2.66 S2
33 -15.62 -26.67 11.05 0.00 0.00 0.00 -22.49 -4.19 13.73 -2.68 S2
10 -15.39 -26.43 11.05 0.00 0.00 0.00 -22.36 -4.08 13.75 -2.71 S2
9 -14.99 -25.01 10.01 0.00 0.00 0.00 -22.05 -2.96 12.66 -2.65 S2
31 -14.30 -24.23 9.94 0.00 0.00 0.00 -20.94 -3.29 12.49 -2.56 S2
14 -14.04 -23.66 9.62 0.00 0.00 0.00 -20.78 -2.88 12.16 -2.53 S2
40 -13.70 -23.14 9.44 0.00 0.00 0.00 -20.30 -2.84 11.94 -2.50 S2
37 -13.37 -20.22 6.85 0.00 0.00 0.00 -19.90 -0.32 9.26 -2.41 S2
11 -13.29 -21.53 8.24 0.00 0.00 0.00 -19.28 -2.25 10.42 -2.18 S2
12 -13.18 -21.91 8.73 0.00 0.00 0.00 -19.55 -2.36 11.04 -2.31 S2
27 -12.68 -19.98 7.30 0.00 0.00 0.00 -18.93 -1.04 9.51 -2.21 S2
Pose # ΔG binding ΔG gas ΔG solv BOND ANGLE DIHED VDWAALS EEL EGB ESURF Region
39 -28.92 -38.49 9.58 0.00 0.00 0.00 -34.56 -3.93 13.68 -4.10 Φhyd
46 -27.59 -35.13 7.54 0.00 0.00 0.00 -33.37 -1.76 11.45 -3.91 Φhyd
49 -25.46 -33.03 7.57 0.00 0.00 0.00 -31.76 -1.28 11.33 -3.76 Φhyd
32 -24.20 -31.96 7.76 0.00 0.00 0.00 -30.65 -1.31 11.45 -3.69 Φhyd
41 -23.43 -35.53 12.09 0.00 0.00 0.00 -30.04 -5.49 15.74 -3.65 Φhyd
34 -16.82 -26.75 9.93 0.00 0.00 0.00 -23.98 -2.77 12.75 -2.82 S2
1 -16.81 -27.05 10.24 0.00 0.00 0.00 -24.04 -3.01 13.08 -2.84 S2
7 -16.66 -25.26 8.60 0.00 0.00 0.00 -24.17 -1.09 11.39 -2.79 S2
19 -16.33 -27.20 10.87 0.00 0.00 0.00 -23.12 -4.07 13.56 -2.69 S2
31 -16.20 -25.11 8.90 0.00 0.00 0.00 -21.98 -3.13 11.41 -2.50 S2
20 -15.77 -25.04 9.27 0.00 0.00 0.00 -22.61 -2.43 11.99 -2.72 S2
15 -15.33 -25.75 10.42 0.00 0.00 0.00 -21.96 -3.79 13.06 -2.63 S2
4 -15.23 -24.62 9.39 0.00 0.00 0.00 -22.31 -2.30 11.96 -2.57 S2






Figure 9: Trajectory of the “tightest” binding poses, as determined by MM-GBSA 
calculations, for A) (+)-zuonin A pose 39, green, and B) (-)-zuonin A pose 
43, orange, with a vector to emphasize the change in orientation. Both are 
bound to Φhyd binding site. 
 
 
Figure 10: Stable binding pose of a) (-)-Zuonin A pose 43 and b) (+)-Zuonin A pose 39. 
Enlarged as Figure S11 
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Over the course of the MD simulation, the docking prediction pose 43 for (-)-
zuonin A assumed a stable conformation with the tetrahydrofuran ring occupying the φA 
site normally occupied by Leu159 of JIP1. Both methyl groups were on the solvent 
facing side of the ring in the vicinity of the φB recognition site. Visualization of pose 
43’s MD trajectory showed that several key movements were necessary to achieve this 
thermodynamically favorable binding mode, figure 9. At the beginning of the simulation, 
one of (-)-zuonin A’s 1,3-benzodioxole rings is originally bound to the φA-X-φB 
recognition site. Rotation of (-)-zuonin A occurs when the upper 1,3-benzodioxole ring 
begins to slide past the residues Val159, Lys160, Ser161 and Asp162 which create the 
upper portion of the pocket. Simultaneously, Glu117-Leu123 undergo a movement in 
their backbone which creates an induced fit hydrophobic pocket available for tighter 
binding of the second 1,3-benzodioxole ring. The (-)-zuonin A molecule then gets 
“locked” into place as Arg127 swings upward toward the first 1,3-benzodioxole ring and 
holds it between its guanidinium cap and the backbone of Asp162 using the side chain of 
Cys163 as a base. 
Decomposing the binding free energy into the contributions from each JNK 
amino acid reveals several significant interactions, table 3. One interaction involves the 
side chain of Val118, -1.787 kcal/mol, which appears to wedge itself between one of (-)-
zuonin A’s methyls and the 1,3-benzodioxole ring bound to the induced hydrophobic 
pocket, figures 10c & 10d. A similar interaction occurs between the backbone of Ser161, 
-1.361 kcal/mol, and the other side of the THF ring. The residues involved in 
immobilizing the other 1,3-benzodioxole ring, Arg127, Asp162, and Cys163, all provide 
major contributions to (-)-zuonin A binding with binding free energies of -1.623, -1.026, 
and -1.243 kcal/mol respectively. Other contributions come from the hydrophobic amino 
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acids that line the inside of both the φA-X-φB recognition site in addition to those that 
line the induced hydrophobic pocket, table 3.  
Table 3: Free energy contributions of JNK1 residues to the binding of (-)-zuonin A once 




The binding free energies calculated for the various (+)-zuonin A trajectories 
suggests that the (+)-zuonin A enantiomer may also prefer binding to the φA-X-φB 
recognition site, but in a different fashion. The two poses with the lowest binding energy 
for (+)-zuonin A were 39 and 46 both adopted very similar binding modes. The THF ring 
still primarily occupies the φA site, however, unlike with (-)-zuonin A, the two methyl 
groups point in toward the hydrophobic core and create a small hydrophobic pocket in the 
same location as the one occupied in the (-)-zuonin A model. Unlike, (-)-zuonin A’s more 
dynamic movement, (+)-zuonin A pose 39 stays relatively stationary except for a 
noticeable dynamic movement of Arg127’s side chain which swings down and away 
Side Chain Backbone







VAL118 -1.787 0.000 -1.719 -0.395 0.563 -0.237 -1.502 -0.286
ARG127 -1.623 0.000 -2.168 -3.704 4.632 -0.384 -1.583 -0.041
LEU123 -1.452 0.000 -1.364 -0.211 0.296 -0.173 -1.332 -0.119
SER161 -1.361 0.000 -2.130 -0.346 1.476 -0.361 -0.148 -1.213
VAL159 -1.258 0.000 -1.405 0.182 0.079 -0.114 -1.073 -0.186
CYS163 -1.243 0.000 -1.514 0.267 0.135 -0.131 -0.737 -0.505
ASP162 -1.026 0.000 -1.120 -0.183 0.364 -0.086 -0.081 -0.945
LEU131 -1.008 0.000 -0.970 -0.106 0.152 -0.083 -0.959 -0.049
MET121 -0.900 0.000 -0.897 -0.690 0.758 -0.071 -0.439 -0.461
LYS160 -0.897 0.000 -1.055 0.072 0.143 -0.056 -0.018 -0.879
ILE119 -0.845 0.000 -0.864 -0.380 0.427 -0.027 -0.265 -0.580
LEU115 -0.652 0.000 -0.645 0.062 -0.044 -0.024 -0.516 -0.135
Side Chain + Backbone Energies
Free Energy Decomposition of (-)-Zuonin A binding
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from the 1,3-benzodioxole ring of (+)-zuonin A, giving the ring space to lay flat on the 
peptide backbone of Cys163, figures 10a & b.  
The large movement of (-)-zuonin A in the Φhyd pocket caused it to have a larger 
standard deviation in its binding free energy (~6 kcal/mol) compared to the other studied 
poses (~2 kcal/mol), Stable 8. The binding free energy of poses 43 for (-)-zuonin A and 
39 for (+)-zuonin A in their most stable states (4-8ns) showed that indeed (-)-zuonin A (-
32 kcal/mol) bound to JNK1 with a slightly lower binding free energy than (+)-zuonin A 
(-30 kcal/mol), Stable 13. 
It is to be noted that entropy contributions are not included in these free energy 
values since current calculation methods are typically time consuming and unreliable. 
Therefore, the free energy values as presented here represent binding enthalpy and 
changes in enthalpy during solvation. 
COMPARISON TO PREVIOUS (-)-ZUONIN A BINDING MODEL 
Lastly, it is important to address a previous (-)-zuonin A/JNK interaction study 
performed by Yan et al.[11] which proposed a model of (-)-zuonin binding where the 
inhibitor was bound to the S2 region of JNK. Residues that were considered important for 
(-)-zuonin A binding to the S2 site were mutated to alanines and kinetic/inhibition assays 
were performed on the mutants. Of the 5 mutants made (R127A, T164A, W324A, 
Y130A, C163A) only the R127A mutant led to altered kinetic parameters for c-Jun 
phosphorylation in the absence of (-)-zuonin A. This data further supports R127’s 






Table 4: (-)-Zuonin A inhibition data for JNK mutants published by Kaoud et al.[11] Km 
kcat and kcat/Km describe the binding and phosphorylation of c-Jun by JNK2. 
IC50 and % inhibition describe the (-)-zuonin A concentration necessary to 
achieve 50% of the maximal inhibition and the maximal percentage of 
inhibition compared to the baseline at saturating concentrations.  
 
Mutants R127A, C163A and T164A are common to both the S2 binding pocket 
and the Φhyd pocket and provide important binding interactions in both models. The 
perturbed binding of c-Jun by the R127A mutant makes it difficult to derive any 
conclusions regarding inhibitor binding, however the IC50 values for mutants C163A and 
T164A both increased by over 1100% and 360% respectively while their maximal 
inhibition was nearly halved clearly showing that these mutations have some effect on 
inhibitor binding which would be expected in either model, table 4. 
An interesting discovery from the previous study was that mutations of the large 
side chain amino acids Y130 and W324 to alanine in the S2 binding pocket did not alter 
c-Jun binding, but increased the percentage inhibition of (-)-zuonin A from 70% when 
complexed with wild type JNK2 to 95% and 98% when bound to the mutants Y130A and 
W324A. Although this result does support the possibility that (-)-zuonin A does indeed 
bind to the S2 pocket, one must also consider the effects that these large mutations had on 
the S2 binding region. 
Mutants K m (μM) k cat (s
-1





JNK2 WT 1.65 ± 0.1 1 ± 0.15 0.6 2.9 ± 0.17 70
JNK2 (R127A) 23.6 ± 1.1 1.4 ± 0.3 0.06 14 ± 2.1 80
JNK2 (Y130A) 1.87 ± 0.3 1 ± 0.04 0.53 2.3 ± 0.16 95
JNK2 (C163A) 1.33 ± 0.4 1 ± 0.065 0.75 37 ± 2.5 37
JNK2 (T164A) 0.73 ± 0.18 1.1 ± 0.064 1.5 13.6 ± 1.5 39
JNK2 (W324A) 2.3 ± 0.15 1.06 ± 0.075 0.46 16.6 ± 0.17 98
JNK2 (D326A) 2 ± 0.83 0.8 ± 0.08 0.4 2.8 ± 0.32 71
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It is not out of the realm of possibility that (-)-zuonin A could sample both the S2 
and Φhyd pocket of WT JNK2, but based on simulation data, may prefer binding to the 
latter. This conformation may be the tightest fit for (-)-zuonin A but its binding mode 
may only inhibit 70% of the reactions that occur. Expanding the S2 binding pocket by 
mutating Y130 and W324 to alanine may increase the probability of (-)-zuonin A binding 
to that region where it can more effectively block c-Jun binding either in a singular 
fashion or by binding to both S2 and Φhyd pockets. 
In order to gain further insight and validation into the Φhyd binding model, it 
would be beneficial to mutate JNK residues that are predicted to contribute the most to (-
)-zuonin binding based on MD simulation data and are unique to the Φhyd region, such as 
Val118, Leu123, and Val 159.  
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Chapter 4: Conclusions 
Previous work has shown that enantiomers (+)-zuonin A and & (-)-zuonin A can 
bind to different JNK isoforms with a high specificity over other MAP kinases and 
disrupt JNK/substrate interactions at the D-recruitment site (DRS). Although they have a 
similar affinity for JNK, (-)-zuonin A inhibits 80% of JNK phosphorylation events, while 
(+)-zuonin A only inhibits 15% at saturated levels. 
 In this study, molecular docking and molecular dynamics simulations were 
utilized to examine binding interactions between JNK and both zuonin A enantiomers 
and to identify differences in their binding modes. First, a series of potential binding 
pockets and poses were determined using molecular docking experiments along the DRS 
using the JNK1-pepJIP1 crystal structure as a guide. Each pose was then subjected to 
molecular dynamics simulations to account for explicit solvent effects and dynamic 
interactions within the system. The trajectories were then used to estimate the binding 
free energy for each pose in hopes of discovering the most likely binding interaction. 
The results support the limitation of docking only experiments which allow for 
free movement of the ligand, but rely heavily on a rigid target structure. MD simulation 
results showed that JNK can alter its structure in the presence of either zuonin enantiomer 
in order to better accommodate binding of the inhibitor. 
Although the results of both simulations have both zuonin A enantiomers binding 
in the same Φhyd region of JNK1’s DRS, they adopt different conformations and have 
different levels of thermodynamic stability. This difference in thermodynamic stability 
may explain why (-)-zuonin A’s increased effectiveness at inhibiting the phosphorylation 
of JNK’s substrates over (+)-zuonin A.  
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In addition, the proposed Φhyd (-)-zuonin A binding model was determined using a 
different method than that used to describe a previous binding model which suggests (-)-
zuonin A binds to the S2 binding region. It is possible that these models are not mutually 
exclusive, but could work in conjunction with one another. To gain a better insight, it 
would be beneficial to physically mutate residues that are unique to the Φhyd pocket and 
predicted to contribute the largest binding interactions for (-)-zuonin A and note any 





























STable 5: Total free energy and decomposition of contributions for each (-)-zuonin 






















9 1116.87 28.63 1.01 3060.12 40.39 1.43 3834.89 23.46 0.83 -2854.83 24.81 0.88
10 1116.32 28.26 1.00 3044.67 41.66 1.47 3833.11 26.16 0.92 -2849.52 23.52 0.83
11 1115.35 27.72 0.98 3057.73 43.01 1.52 3829.32 24.93 0.88 -2845.69 23.36 0.83
12 1117.25 27.82 0.98 3058.82 42.55 1.50 3833.13 26.26 0.93 -2871.83 29.37 1.04
14 1115.32 28.42 1.00 3048.20 42.37 1.50 3827.03 25.91 0.92 -2853.19 24.20 0.86
24 1115.58 27.13 0.96 3055.55 42.54 1.50 3827.71 23.69 0.84 -2854.35 33.21 1.17
27 1116.51 28.44 1.01 3053.99 42.47 1.50 3837.28 25.15 0.89 -2844.92 26.03 0.92
31 1115.00 28.72 1.02 3044.72 41.32 1.46 3837.95 24.06 0.85 -2851.73 27.74 0.98
33 1113.09 28.37 1.00 3053.08 42.81 1.51 3830.55 24.88 0.88 -2850.82 26.72 0.94
37 1115.70 28.45 1.01 3059.60 42.30 1.50 3827.67 26.09 0.92 -2845.98 26.05 0.92
40 1114.22 28.12 0.99 3057.44 42.22 1.49 3829.82 25.14 0.89 -2852.76 27.63 0.98
43 1116.83 28.65 1.01 3058.74 43.69 1.54 3828.86 24.60 0.87 -2872.18 26.78 0.95
44 1117.80 28.72 1.02 3062.70 42.43 1.50 3836.09 26.20 0.93 -2865.94 31.89 1.13
















9 -26160.93 150.73 5.33 -4589.06 122.35 4.33 134.05 2.42 0.09
10 -26114.98 98.33 3.48 -4620.97 79.10 2.80 135.95 1.84 0.07
11 -26014.34 154.11 5.45 -4714.22 119.42 4.22 137.42 2.08 0.07
12 -25989.07 101.29 3.58 -4684.78 85.23 3.01 133.43 2.27 0.08
14 -26087.91 134.51 4.76 -4605.07 98.04 3.47 135.34 2.11 0.07
24 -26036.06 180.48 6.38 -4703.65 136.60 4.83 137.18 3.35 0.12
27 -26075.19 137.20 4.85 -4660.65 132.13 4.67 136.67 2.18 0.08
31 -26058.48 92.15 3.26 -4658.85 74.93 2.65 137.46 2.64 0.09
33 -26034.71 135.47 4.79 -4693.68 104.51 3.69 134.98 2.53 0.09
37 -25944.50 104.86 3.71 -4768.40 80.88 2.86 136.54 2.17 0.08
40 -26098.86 106.08 3.75 -4636.00 78.89 2.79 134.82 2.36 0.08
43 -26028.17 168.35 5.95 -4697.32 112.12 3.96 133.29 2.85 0.10
44 -25884.75 133.68 4.73 -4780.74 115.73 4.09 134.92 3.09 0.11
















9 -21003.87 162.28 5.74 -4455.02 122.38 4.33 -25458.89 56.69 2.00
10 -20970.41 115.94 4.10 -4485.01 79.12 2.80 -25455.42 54.50 1.93
11 -20857.63 165.94 5.87 -4576.81 119.44 4.22 -25434.44 61.19 2.16
12 -20851.70 119.99 4.24 -4551.35 85.26 3.01 -25403.05 58.93 2.08
14 -20950.55 148.17 5.24 -4469.73 98.06 3.47 -25420.29 57.54 2.03
24 -20891.57 191.79 6.78 -4566.47 136.64 4.83 -25458.04 63.15 2.23
27 -20912.34 150.82 5.33 -4523.98 132.15 4.67 -25436.32 57.21 2.02
31 -20912.55 111.23 3.93 -4521.39 74.98 2.65 -25433.94 61.58 2.18
33 -20888.81 149.41 5.28 -4558.70 104.54 3.70 -25447.51 63.82 2.26
37 -20787.51 122.28 4.32 -4631.86 80.91 2.86 -25419.37 57.15 2.02
40 -20950.16 123.37 4.36 -4501.18 78.93 2.79 -25451.34 59.04 2.09
43 -20895.93 179.98 6.36 -4564.04 112.16 3.97 -25459.97 62.91 2.22
44 -20734.11 148.99 5.27 -4645.81 115.77 4.09 -25379.92 60.49 2.14








STable 6: Total free energy and decomposition of contributions of the receptor, JNK1, 






















9 1105.25 28.38 1.00 3012.26 40.18 1.42 3811.43 23.48 0.83 -2829.38 24.99 0.88
10 1104.70 28.12 0.99 2997.11 41.58 1.47 3809.88 25.94 0.92 -2823.72 23.45 0.83
11 1103.90 27.67 0.98 3009.46 42.97 1.52 3806.46 24.98 0.88 -2822.78 23.61 0.83
12 1105.65 27.74 0.98 3010.77 42.44 1.50 3809.79 26.02 0.92 -2848.87 29.47 1.04
14 1103.80 28.21 1.00 3000.22 42.17 1.49 3803.75 25.91 0.92 -2829.07 24.09 0.85
24 1104.18 26.97 0.95 3007.80 42.55 1.50 3804.07 23.72 0.84 -2828.34 33.07 1.17
27 1104.95 28.24 1.00 3005.98 42.27 1.49 3813.57 24.98 0.88 -2822.50 25.68 0.91
31 1103.60 28.49 1.01 2996.65 41.20 1.46 3814.75 24.05 0.85 -2827.23 27.19 0.96
33 1101.66 28.10 0.99 3005.35 42.77 1.51 3807.31 24.87 0.88 -2824.92 26.39 0.93
37 1104.15 28.38 1.00 3011.91 42.09 1.49 3804.30 25.93 0.92 -2822.70 25.94 0.92
40 1102.80 28.05 0.99 3009.72 42.06 1.49 3806.57 25.07 0.89 -2829.14 27.92 0.99
43 1105.44 28.42 1.01 3010.93 43.44 1.54 3805.51 24.49 0.87 -2835.54 25.21 0.89
44 1106.34 28.62 1.01 3014.58 42.20 1.49 3812.81 26.04 0.92 -2839.24 32.21 1.14
















9 -26058.73 150.79 5.33 -4586.80 123.05 4.35 133.91 2.48 0.09
10 -26010.73 98.66 3.49 -4620.65 79.28 2.80 135.87 1.83 0.06
11 -25910.55 153.15 5.41 -4710.16 119.72 4.23 136.80 2.12 0.07
12 -25889.16 101.27 3.58 -4681.21 84.81 3.00 132.96 2.30 0.08
14 -25985.58 134.37 4.75 -4602.56 98.07 3.47 135.09 2.10 0.07
24 -25931.59 179.85 6.36 -4702.26 136.51 4.83 137.06 3.35 0.12
27 -25974.06 137.48 4.86 -4655.20 132.14 4.67 136.10 2.13 0.08
31 -25952.55 91.89 3.25 -4656.86 75.13 2.66 137.23 2.64 0.09
33 -25929.34 136.58 4.83 -4693.11 104.45 3.69 134.87 2.52 0.09
37 -25846.42 104.84 3.71 -4762.80 80.97 2.86 136.17 2.16 0.08
40 -25995.89 105.90 3.74 -4633.11 79.25 2.80 134.54 2.41 0.09
43 -25919.34 166.06 5.87 -4698.30 109.36 3.87 134.37 2.48 0.09
44 -25786.00 134.18 4.74 -4774.93 115.98 4.10 134.97 3.20 0.11
















9 -20959.17 162.28 5.74 -4452.89 123.08 4.35 -25412.06 56.20 1.99
10 -20922.76 116.09 4.10 -4484.77 79.30 2.80 -25407.54 54.19 1.92
11 -20813.50 165.07 5.84 -4573.35 119.74 4.23 -25386.86 61.36 2.17
12 -20811.81 119.88 4.24 -4548.24 84.84 3.00 -25360.06 58.66 2.07
14 -20906.87 147.93 5.23 -4467.47 98.09 3.47 -25374.34 57.40 2.03
24 -20843.88 191.15 6.76 -4565.20 136.55 4.83 -25409.07 63.02 2.23
27 -20872.06 150.89 5.33 -4519.10 132.15 4.67 -25391.16 56.58 2.00
31 -20864.77 110.77 3.92 -4519.63 75.18 2.66 -25384.41 61.17 2.16
33 -20839.95 150.29 5.31 -4558.24 104.48 3.69 -25398.18 63.42 2.24
37 -20748.76 122.12 4.32 -4626.64 81.00 2.86 -25375.40 56.88 2.01
40 -20905.94 123.20 4.36 -4498.56 79.29 2.80 -25404.50 59.05 2.09
43 -20833.01 177.50 6.28 -4563.93 109.38 3.87 -25396.93 60.54 2.14
44 -20691.52 149.40 5.28 -4639.96 116.02 4.10 -25331.48 60.44 2.14
45 -20937.69 171.18 6.05 -4427.86 120.10 4.25 -25365.56 64.44 2.28
G gas G solv TOTAL
JNK1 (Receptor)
EEL EGB ESURF
BOND ANGLE DIHED VDWAALS
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STable 7: Total free energy and decomposition of contributions of the ligand, (-)-zuonin 






















9 11.62 2.91 0.10 47.86 3.65 0.13 23.47 2.31 0.08 -3.40 1.00 0.04
10 11.62 2.87 0.10 47.56 3.89 0.14 23.23 2.36 0.08 -3.45 0.96 0.03
11 11.44 2.79 0.10 48.27 3.66 0.13 22.86 2.22 0.08 -3.63 0.95 0.03
12 11.59 2.83 0.10 48.06 3.76 0.13 23.34 2.27 0.08 -3.41 0.95 0.03
14 11.52 2.79 0.10 47.97 3.63 0.13 23.27 2.34 0.08 -3.34 1.03 0.04
24 11.39 2.70 0.10 47.75 4.02 0.14 23.64 2.30 0.08 -3.54 0.91 0.03
27 11.56 3.01 0.11 48.01 3.85 0.14 23.71 2.61 0.09 -3.49 0.97 0.03
31 11.39 2.96 0.10 48.07 3.69 0.13 23.19 2.42 0.09 -3.55 0.93 0.03
33 11.43 2.80 0.10 47.73 3.96 0.14 23.23 2.38 0.08 -3.41 0.97 0.03
37 11.55 2.90 0.10 47.68 3.72 0.13 23.37 2.34 0.08 -3.37 0.94 0.03
40 11.41 2.92 0.10 47.72 3.76 0.13 23.25 2.23 0.08 -3.33 0.97 0.03
43 11.39 2.85 0.10 47.81 3.76 0.13 23.35 2.28 0.08 -3.71 0.85 0.03
44 11.46 2.84 0.10 48.12 3.95 0.14 23.28 2.29 0.08 -3.49 0.98 0.03
















9 -99.24 1.86 0.07 -14.92 0.64 0.02 2.78 0.03 0.00
10 -100.17 1.71 0.06 -14.07 0.63 0.02 2.79 0.02 0.00
11 -101.54 2.72 0.10 -14.48 0.63 0.02 2.79 0.02 0.00
12 -97.55 2.05 0.07 -14.62 0.64 0.02 2.78 0.02 0.00
14 -99.46 2.30 0.08 -14.67 0.62 0.02 2.78 0.02 0.00
24 -99.79 1.78 0.06 -14.99 0.53 0.02 2.78 0.02 0.00
27 -100.09 1.80 0.06 -14.95 0.48 0.02 2.78 0.03 0.00
31 -102.65 2.85 0.10 -14.48 0.58 0.02 2.79 0.02 0.00
33 -101.18 2.42 0.09 -14.30 0.67 0.02 2.78 0.02 0.00
37 -97.76 2.40 0.08 -14.86 0.56 0.02 2.78 0.02 0.00
40 -100.14 2.24 0.08 -14.84 0.52 0.02 2.78 0.02 0.00
43 -103.47 1.80 0.06 -14.71 0.47 0.02 2.78 0.02 0.00
44 -99.14 2.19 0.08 -14.73 0.64 0.02 2.78 0.02 0.00
















9 -19.70 5.62 0.20 -12.14 0.64 0.02 -31.84 4.47 0.16
10 -21.21 5.73 0.20 -11.29 0.63 0.02 -32.49 4.67 0.17
11 -22.60 5.87 0.21 -11.70 0.63 0.02 -34.29 4.52 0.16
12 -17.98 5.70 0.20 -11.84 0.64 0.02 -29.82 4.65 0.16
14 -20.02 5.73 0.20 -11.89 0.62 0.02 -31.91 4.65 0.16
24 -20.54 5.72 0.20 -12.21 0.53 0.02 -32.76 4.57 0.16
27 -20.31 5.90 0.21 -12.17 0.48 0.02 -32.48 4.90 0.17
31 -23.54 6.10 0.22 -11.70 0.58 0.02 -35.24 4.78 0.17
33 -22.19 5.99 0.21 -11.52 0.67 0.02 -33.71 4.49 0.16
37 -18.53 5.86 0.21 -12.08 0.56 0.02 -30.60 4.58 0.16
40 -21.08 5.80 0.21 -12.06 0.53 0.02 -33.14 4.66 0.16
43 -24.63 5.60 0.20 -11.93 0.47 0.02 -36.55 4.62 0.16
44 -19.77 5.88 0.21 -11.95 0.64 0.02 -31.72 4.76 0.17
45 -19.59 5.98 0.21 -11.88 0.64 0.02 -31.47 4.74 0.17
(-)-Zuonin A (Ligand)
BOND ANGLE DIHED VDWAALS
EEL EGB ESURF
G gas G solv TOTAL
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STable 8: Binding free energy of (-)-zuonin A to JNK1 calculated by taking the 






















9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -22.05 2.85 0.10
10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -22.36 2.07 0.07
11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -19.28 3.08 0.11
12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -19.55 2.65 0.09
14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -20.78 2.38 0.08
24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -22.48 2.43 0.09
27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -18.93 2.59 0.09
31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -20.94 2.67 0.09
33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -22.49 2.57 0.09
37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -19.90 2.45 0.09
40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -20.30 2.26 0.08
43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -32.93 6.86 0.24
44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -23.20 3.12 0.11
















9 -2.96 3.20 0.11 12.66 3.50 0.12 -2.65 0.30 0.01
10 -4.08 1.99 0.07 13.75 2.12 0.08 -2.71 0.20 0.01
11 -2.25 2.09 0.07 10.42 2.06 0.07 -2.18 0.37 0.01
12 -2.36 2.01 0.07 11.04 2.18 0.08 -2.31 0.30 0.01
14 -2.88 1.91 0.07 12.16 1.99 0.07 -2.53 0.24 0.01
24 -4.68 2.39 0.08 13.61 2.55 0.09 -2.66 0.23 0.01
27 -1.04 2.57 0.09 9.51 2.33 0.08 -2.21 0.26 0.01
31 -3.29 2.73 0.10 12.49 2.64 0.09 -2.56 0.29 0.01
33 -4.19 2.07 0.07 13.73 2.26 0.08 -2.68 0.27 0.01
37 -0.32 2.67 0.09 9.26 2.19 0.08 -2.41 0.27 0.01
40 -2.84 2.13 0.08 11.94 2.40 0.09 -2.50 0.25 0.01
43 -5.37 3.81 0.13 15.69 4.65 0.16 -3.87 0.70 0.02
44 0.40 2.77 0.10 8.92 2.25 0.08 -2.83 0.42 0.01
















9 -25.01 4.29 0.15 10.01 3.51 0.12 -14.99 2.41 0.09
10 -26.43 2.87 0.10 11.05 2.13 0.08 -15.39 1.88 0.07
11 -21.53 3.72 0.13 8.24 2.09 0.07 -13.29 2.67 0.09
12 -21.91 3.32 0.12 8.73 2.20 0.08 -13.18 2.02 0.07
14 -23.66 3.05 0.11 9.62 2.00 0.07 -14.04 1.96 0.07
24 -27.16 3.41 0.12 10.94 2.56 0.09 -16.21 2.02 0.07
27 -19.98 3.65 0.13 7.30 2.35 0.08 -12.68 2.31 0.08
31 -24.23 3.82 0.14 9.94 2.66 0.09 -14.30 2.19 0.08
33 -26.67 3.30 0.12 11.05 2.27 0.08 -15.62 2.28 0.08
37 -20.22 3.62 0.13 6.85 2.21 0.08 -13.37 1.87 0.07
40 -23.14 3.10 0.11 9.44 2.42 0.09 -13.70 1.78 0.06
43 -38.30 7.84 0.28 11.82 4.71 0.17 -26.48 6.36 0.22
44 -22.81 4.17 0.15 6.09 2.29 0.08 -16.72 2.53 0.09
45 -30.77 3.55 0.13 8.55 1.93 0.07 -22.22 2.84 0.10
Difference (Complex - Receptor - Ligand) [(-)-Zuonin A/JNK1]
BOND ANGLE DIHED VDWAALS
EEL EGB ESURF
ΔG gas ΔG solv ΔG binding
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STable 9: Total free energy and decomposition of contributions for each (+)-zuonin 






















1 1113.88 28.48 1.01 3057.08 42.19 1.49 3831.70 26.32 0.93 -2878.97 26.79 0.95
4 1115.19 28.02 0.99 3052.19 43.67 1.54 3831.22 26.26 0.93 -2845.69 28.69 1.01
7 1115.30 27.91 0.99 3065.93 42.10 1.49 3838.74 25.71 0.91 -2869.92 25.13 0.89
15 1116.19 28.77 1.02 3059.38 40.66 1.44 3833.36 25.37 0.90 -2861.33 28.68 1.01
19 1115.71 27.58 0.98 3056.93 43.52 1.54 3829.07 24.68 0.87 -2878.89 28.52 1.01
20 1117.37 28.68 1.01 3057.94 41.02 1.45 3825.86 25.10 0.89 -2836.37 23.39 0.83
22 1117.11 29.88 1.06 3057.99 41.39 1.46 3831.70 24.77 0.88 -2852.73 27.04 0.96
31 1112.81 29.32 1.04 3045.51 42.56 1.50 3838.84 24.57 0.87 -2869.71 24.65 0.87
32 1117.05 27.94 0.99 3058.64 42.60 1.51 3823.75 26.58 0.94 -2860.23 27.92 0.99
34 1118.73 28.04 0.99 3059.41 42.76 1.51 3811.32 26.61 0.94 -2831.49 30.35 1.07
39 1115.96 27.04 0.96 3052.43 41.85 1.48 3834.32 23.57 0.83 -2897.22 27.83 0.98
41 1112.78 27.46 0.97 3049.85 42.81 1.51 3838.48 23.65 0.84 -2876.38 25.64 0.91
46 1116.29 28.89 1.02 3055.28 42.26 1.49 3838.88 27.17 0.96 -2866.88 23.31 0.82
















1 -26187.02 107.09 3.79 -4550.76 91.00 3.22 131.50 2.86 0.10
4 -26024.35 163.50 5.78 -4692.13 117.26 4.15 136.17 2.48 0.09
7 -26278.14 138.35 4.89 -4479.34 99.17 3.51 130.35 2.36 0.08
15 -26003.99 102.74 3.63 -4702.27 96.58 3.41 133.88 2.55 0.09
19 -26111.23 129.89 4.59 -4570.14 90.84 3.21 131.98 2.55 0.09
20 -26039.55 129.30 4.57 -4676.99 101.81 3.60 136.95 2.02 0.07
22 -26018.49 145.87 5.16 -4666.65 109.76 3.88 134.99 2.91 0.10
31 -25970.35 126.65 4.48 -4726.50 94.28 3.33 135.27 2.10 0.07
32 -26012.22 91.49 3.23 -4658.35 82.23 2.91 134.34 2.56 0.09
34 -25979.75 111.29 3.93 -4719.61 91.82 3.25 137.68 2.80 0.10
39 -26167.21 154.91 5.48 -4537.97 131.57 4.65 129.64 3.11 0.11
41 -25909.06 112.08 3.96 -4759.05 89.69 3.17 135.01 2.35 0.08
46 -26068.33 145.74 5.15 -4606.14 94.68 3.35 132.87 1.83 0.06
















1 -21063.32 124.37 4.40 -4419.25 91.04 3.22 -25482.58 65.54 2.32
4 -20871.43 175.89 6.22 -4555.97 117.29 4.15 -25427.40 68.55 2.42
7 -21128.10 151.61 5.36 -4349.00 99.20 3.51 -25477.10 59.22 2.09
15 -20856.39 120.43 4.26 -4568.40 96.62 3.42 -25424.78 63.01 2.23
19 -20988.41 144.74 5.12 -4438.16 90.87 3.21 -25426.57 62.44 2.21
20 -20874.75 142.84 5.05 -4540.04 101.83 3.60 -25414.79 59.13 2.09
22 -20864.42 158.83 5.62 -4531.67 109.80 3.88 -25396.09 65.14 2.30
31 -20842.89 141.15 4.99 -4591.23 94.30 3.33 -25434.13 57.72 2.04
32 -20873.01 111.59 3.95 -4524.01 82.27 2.91 -25397.02 59.86 2.12
34 -20821.79 128.95 4.56 -4581.93 91.86 3.25 -25403.72 59.90 2.12
39 -21061.72 166.77 5.90 -4408.34 131.61 4.65 -25470.06 62.97 2.23
41 -20784.32 127.92 4.52 -4624.03 89.73 3.17 -25408.35 56.49 2.00
46 -20924.77 158.57 5.61 -4473.28 94.69 3.35 -25398.05 62.16 2.20
49 -21232.02 177.86 6.29 -4257.86 138.82 4.91 -25489.88 70.22 2.48
G gas G solv TOTAL
(+)-Zuonin A/JNK1 Complex




STable 10: Total free energy and decomposition of contributions of the receptor, JNK1, 






















1 1102.40 28.42 1.00 3008.38 41.81 1.48 3808.96 26.28 0.93 -2851.44 27.05 0.96
4 1103.84 27.96 0.99 3003.91 43.46 1.54 3808.30 26.10 0.92 -2820.15 28.21 1.00
7 1103.87 27.79 0.98 3017.49 41.97 1.48 3816.03 25.43 0.90 -2842.33 25.19 0.89
15 1104.66 28.65 1.01 3011.30 40.14 1.42 3810.14 25.37 0.90 -2835.97 28.94 1.02
19 1104.59 27.49 0.97 3008.59 43.55 1.54 3806.24 24.63 0.87 -2852.21 28.77 1.02
20 1105.88 28.55 1.01 3009.62 41.10 1.45 3802.83 25.13 0.89 -2810.19 23.29 0.82
22 1105.73 29.63 1.05 3009.86 41.17 1.46 3808.93 24.74 0.87 -2829.26 26.88 0.95
31 1101.62 29.32 1.04 2997.07 42.38 1.50 3816.00 24.57 0.87 -2844.17 24.72 0.87
32 1105.81 27.75 0.98 3010.67 42.50 1.50 3800.88 26.51 0.94 -2825.89 27.41 0.97
34 1107.36 27.88 0.99 3010.74 42.55 1.50 3788.68 26.40 0.93 -2804.03 29.94 1.06
39 1104.64 26.89 0.95 3004.83 41.73 1.48 3811.22 23.42 0.83 -2858.98 27.35 0.97
41 1101.51 27.56 0.97 3001.69 42.38 1.50 3815.22 23.51 0.83 -2842.72 25.69 0.91
46 1104.90 28.66 1.01 3007.64 42.12 1.49 3815.79 27.24 0.96 -2829.86 23.22 0.82
















1 -26101.34 106.64 3.77 -4550.31 91.30 3.23 131.56 2.91 0.10
4 -25938.67 163.77 5.79 -4690.66 116.96 4.14 135.96 2.36 0.08
7 -26192.31 138.74 4.91 -4477.40 99.49 3.52 130.34 2.35 0.08
15 -25921.63 103.10 3.65 -4701.37 96.54 3.41 133.73 2.53 0.09
19 -26025.05 129.55 4.58 -4569.99 90.60 3.20 131.89 2.56 0.09
20 -25954.77 129.26 4.57 -4675.35 101.88 3.60 136.88 1.99 0.07
22 -25932.70 146.36 5.17 -4663.00 110.39 3.90 134.53 2.96 0.10
31 -25887.86 126.06 4.46 -4724.16 94.19 3.33 134.99 2.07 0.07
32 -25926.55 91.13 3.22 -4656.39 81.81 2.89 135.24 2.56 0.09
34 -25895.11 111.27 3.93 -4718.77 91.66 3.24 137.71 2.75 0.10
39 -26078.93 155.48 5.50 -4538.28 132.51 4.69 130.95 3.07 0.11
41 -25820.86 111.71 3.95 -4761.30 89.74 3.17 135.88 2.37 0.08
46 -25982.30 146.09 5.17 -4604.19 94.85 3.35 133.99 1.79 0.06
















1 -21033.04 123.90 4.38 -4418.75 91.35 3.23 -25451.79 65.45 2.31
4 -20842.78 175.98 6.22 -4554.70 116.98 4.14 -25397.48 67.87 2.40
7 -21097.25 151.87 5.37 -4347.06 99.51 3.52 -25444.30 58.89 2.08
15 -20831.50 120.59 4.26 -4567.64 96.58 3.41 -25399.14 62.98 2.23
19 -20957.84 144.46 5.11 -4438.11 90.64 3.20 -25395.95 62.42 2.21
20 -20846.64 142.78 5.05 -4538.47 101.90 3.60 -25385.11 59.21 2.09
22 -20837.44 159.15 5.63 -4528.47 110.42 3.90 -25365.91 64.56 2.28
31 -20817.34 140.58 4.97 -4589.17 94.21 3.33 -25406.51 57.79 2.04
32 -20835.08 111.06 3.93 -4521.15 81.85 2.89 -25356.23 59.53 2.10
34 -20792.36 128.70 4.55 -4581.06 91.70 3.24 -25373.41 59.35 2.10
39 -21017.21 167.14 5.91 -4407.32 132.55 4.69 -25424.53 62.39 2.21
41 -20745.15 127.47 4.51 -4625.42 89.77 3.17 -25370.58 56.71 2.01
46 -20883.83 158.80 5.61 -4470.20 94.87 3.35 -25354.03 61.65 2.18
49 -21193.36 178.05 6.30 -4254.81 139.06 4.92 -25448.17 70.34 2.49
EEL EGB ESURF
G gas G solv TOTAL
JNK1 (Receptor)
BOND ANGLE DIHED VDWAALS
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STable 11: Total free energy and decomposition of contributions of the ligand, (+)-






















1 11.48 2.93 0.10 48.70 3.83 0.14 22.74 2.28 0.08 -3.49 0.98 0.03
4 11.35 2.87 0.10 48.27 4.02 0.14 22.93 2.30 0.08 -3.22 1.03 0.04
7 11.43 2.83 0.10 48.44 3.98 0.14 22.71 2.20 0.08 -3.42 0.94 0.03
15 11.53 2.89 0.10 48.08 4.01 0.14 23.21 2.34 0.08 -3.39 0.96 0.03
19 11.12 2.83 0.10 48.35 3.68 0.13 22.83 2.18 0.08 -3.56 0.95 0.03
20 11.49 2.80 0.10 48.33 3.68 0.13 23.03 2.34 0.08 -3.57 0.97 0.03
22 11.38 2.82 0.10 48.13 3.74 0.13 22.77 2.11 0.07 -3.72 0.92 0.03
31 11.19 2.77 0.10 48.44 3.77 0.13 22.84 2.29 0.08 -3.56 0.98 0.03
32 11.24 2.83 0.10 47.96 3.72 0.13 22.88 2.14 0.08 -3.69 0.92 0.03
34 11.37 2.91 0.10 48.66 3.78 0.13 22.64 2.21 0.08 -3.48 0.95 0.03
39 11.32 2.82 0.10 47.60 3.79 0.13 23.10 2.24 0.08 -3.68 0.88 0.03
41 11.27 2.65 0.09 48.16 3.76 0.13 23.26 2.23 0.08 -3.62 0.92 0.03
46 11.39 2.81 0.10 47.64 3.75 0.13 23.08 2.16 0.08 -3.66 0.93 0.03
















1 -82.67 2.39 0.08 -13.53 0.50 0.02 2.79 0.02 0.00
4 -83.37 2.84 0.10 -13.43 0.53 0.02 2.78 0.02 0.00
7 -84.75 1.86 0.07 -13.33 0.47 0.02 2.79 0.02 0.00
15 -78.57 1.70 0.06 -13.96 0.48 0.02 2.78 0.02 0.00
19 -82.11 2.25 0.08 -13.71 0.50 0.02 2.79 0.02 0.00
20 -82.35 2.33 0.08 -13.62 0.50 0.02 2.79 0.02 0.00
22 -83.72 1.82 0.06 -13.52 0.48 0.02 2.79 0.02 0.00
31 -79.36 2.00 0.07 -13.75 0.43 0.02 2.78 0.02 0.00
32 -84.36 1.56 0.06 -13.41 0.45 0.02 2.79 0.02 0.00
34 -81.87 2.19 0.08 -13.59 0.48 0.02 2.79 0.02 0.00
39 -84.35 1.48 0.05 -13.37 0.40 0.01 2.79 0.02 0.00
41 -82.71 2.31 0.08 -13.49 0.47 0.02 2.79 0.02 0.00
46 -84.27 1.55 0.05 -13.40 0.43 0.02 2.79 0.02 0.00
















1 -3.23 5.93 0.21 -10.74 0.50 0.02 -13.98 4.57 0.16
4 -4.04 6.23 0.22 -10.65 0.53 0.02 -14.69 4.81 0.17
7 -5.60 5.75 0.20 -10.54 0.47 0.02 -16.14 4.46 0.16
15 0.86 5.80 0.21 -11.18 0.48 0.02 -10.32 4.74 0.17
19 -3.37 5.68 0.20 -10.92 0.50 0.02 -14.28 4.55 0.16
20 -3.07 5.76 0.20 -10.84 0.50 0.02 -13.91 4.72 0.17
22 -5.16 5.53 0.20 -10.74 0.48 0.02 -15.90 4.61 0.16
31 -0.44 5.66 0.20 -10.97 0.44 0.02 -11.41 4.75 0.17
32 -5.97 5.44 0.19 -10.62 0.45 0.02 -16.59 4.44 0.16
34 -2.68 5.78 0.20 -10.80 0.48 0.02 -13.48 4.51 0.16
39 -6.02 5.50 0.19 -10.59 0.40 0.01 -16.61 4.57 0.16
41 -3.64 5.68 0.20 -10.70 0.47 0.02 -14.34 4.65 0.16
46 -5.81 5.47 0.19 -10.62 0.43 0.02 -16.43 4.58 0.16
49 -5.63 5.49 0.19 -10.62 0.42 0.01 -16.24 4.49 0.16
G gas G solv TOTAL
(+)-Zuonin A (Ligand)




STable 12: Binding free energy of (+)-zuonin A to JNK1 calculated by taking the 






















1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -24.04 2.99 0.11
4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -22.31 2.71 0.10
7 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -24.17 2.44 0.09
15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -21.96 2.73 0.10
19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -23.12 2.67 0.09
20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -22.61 3.09 0.11
22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -19.75 1.91 0.07
31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -21.98 2.38 0.08
32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -30.65 3.60 0.13
34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -23.98 2.91 0.10
39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -34.56 3.17 0.11
41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -30.04 2.69 0.10
46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -33.37 3.58 0.13
















1 -3.01 2.23 0.08 13.08 1.98 0.07 -2.84 0.25 0.01
4 -2.30 2.82 0.10 11.96 2.86 0.10 -2.57 0.29 0.01
7 -1.09 1.94 0.07 11.39 1.70 0.06 -2.79 0.21 0.01
15 -3.79 2.42 0.09 13.06 2.50 0.09 -2.63 0.26 0.01
19 -4.07 2.18 0.08 13.56 2.40 0.08 -2.69 0.24 0.01
20 -2.43 2.19 0.08 11.99 2.11 0.07 -2.72 0.28 0.01
22 -2.08 2.66 0.09 9.87 2.63 0.09 -2.33 0.23 0.01
31 -3.13 2.28 0.08 11.41 2.58 0.09 -2.50 0.28 0.01
32 -1.31 1.84 0.07 11.45 1.87 0.07 -3.69 0.36 0.01
34 -2.77 2.29 0.08 12.75 2.02 0.07 -2.82 0.24 0.01
39 -3.93 3.83 0.14 13.68 3.81 0.13 -4.10 0.30 0.01
41 -5.49 2.25 0.08 15.74 2.25 0.08 -3.65 0.35 0.01
46 -1.76 2.01 0.07 11.45 1.50 0.05 -3.91 0.29 0.01
















1 -27.05 3.73 0.13 10.24 1.99 0.07 -16.81 2.38 0.08
4 -24.62 3.91 0.14 9.39 2.88 0.10 -15.23 2.28 0.08
7 -25.26 3.12 0.11 8.60 1.71 0.06 -16.66 2.04 0.07
15 -25.75 3.65 0.13 10.42 2.51 0.09 -15.33 2.34 0.08
19 -27.20 3.45 0.12 10.87 2.41 0.09 -16.33 2.27 0.08
20 -25.04 3.79 0.13 9.27 2.13 0.08 -15.77 2.38 0.08
22 -21.82 3.27 0.12 7.54 2.64 0.09 -14.28 1.79 0.06
31 -25.11 3.29 0.12 8.90 2.60 0.09 -16.20 2.02 0.07
32 -31.96 4.04 0.14 7.76 1.91 0.07 -24.20 3.47 0.12
34 -26.75 3.71 0.13 9.93 2.03 0.07 -16.82 2.49 0.09
39 -38.49 4.97 0.18 9.58 3.82 0.14 -28.92 3.09 0.11
41 -35.53 3.51 0.12 12.09 2.27 0.08 -23.43 2.64 0.09
46 -35.13 4.10 0.15 7.54 1.53 0.05 -27.59 3.56 0.13
49 -33.03 3.54 0.13 7.57 1.55 0.05 -25.46 3.00 0.11
Difference (Complex - Receptor - Ligand) [(+)-Zuonin A/JNK1]
BOND ANGLE DIHED VDWAALS
EEL EGB ESURF
ΔG gas ΔG solv ΔG binding
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STable 13: Total binding free energy contributions calculated from 4-8ns for (-)-zuonin A 



























BOND 1115.96 29.54 1.58 1116.78 28.66 1.53 BOND 1104.75 29.43 1.57 1105.35 28.60 1.53
ANGLE 3051.22 41.79 2.23 3059.31 43.41 2.32 ANGLE 3003.89 41.58 2.22 3011.55 43.22 2.31
DIHED 3825.08 24.66 1.32 3821.00 23.26 1.24 DIHED 3801.72 24.62 1.32 3798.01 23.18 1.24
VDWAALS -2867.76 23.86 1.28 -2880.53 24.73 1.32 VDWAALS -2828.78 23.84 1.27 -2838.42 24.56 1.31
EEL -26167.71 112.17 6.00 -26158.62 121.20 6.48 EEL -26082.24 112.05 5.99 -26046.53 121.13 6.47
1-4 VDW 1339.32 16.51 0.88 1339.80 16.22 0.87 1-4 VDW 1328.44 16.52 0.88 1329.00 16.13 0.86
1-4 EEL 15921.76 43.47 2.32 16008.82 51.10 2.73 1-4 EEL 15783.83 43.34 2.32 15831.87 51.11 2.73
EGB -4549.74 85.67 4.58 -4613.13 82.21 4.39 EGB -4547.60 85.72 4.58 -4617.98 82.17 4.39
ESURF 136.35 1.60 0.09 134.11 2.16 0.12 ESURF 136.99 1.58 0.08 134.96 2.15 0.11
G gas -3782.13 109.81 5.87 -3693.45 102.21 5.46 G gas -3888.39 109.30 5.84 -3809.17 102.05 5.45
G solv -4413.39 84.93 4.54 -4479.02 82.55 4.41 G solv -4410.62 85.02 4.54 -4483.03 82.49 4.41

















BOND 11.21 2.76 0.15 11.42 2.90 0.16 BOND 0.00 0.00 0.00 0.00 0.00 0.00
ANGLE 47.33 3.70 0.20 47.75 3.84 0.21 ANGLE 0.00 0.00 0.00 0.00 0.00 0.00
DIHED 23.36 2.13 0.11 22.99 2.00 0.11 DIHED 0.00 0.01 0.00 0.00 0.01 0.00
VDWAALS -3.67 0.89 0.05 -3.82 0.80 0.04 VDWAALS -35.31 2.35 0.13 -38.29 2.31 0.12
EEL -84.08 1.45 0.08 -103.65 1.55 0.08 EEL -1.39 2.02 0.11 -8.43 2.03 0.11
1-4 VDW 10.88 1.00 0.05 10.79 0.99 0.05 1-4 VDW 0.00 0.00 0.00 0.00 0.00 0.00
1-4 EEL 137.93 1.63 0.09 176.95 1.74 0.09 1-4 EEL 0.00 0.00 0.00 0.00 0.00 0.00
EGB -13.44 0.41 0.02 -14.78 0.44 0.02 EGB 11.30 1.49 0.08 19.63 1.72 0.09
ESURF 4.16 0.03 0.00 4.16 0.03 0.00 ESURF -4.79 0.19 0.01 -5.00 0.13 0.01
G gas 142.96 4.55 0.24 162.43 4.70 0.25 DELTA G gas -36.70 3.11 0.17 -46.72 3.22 0.17
G solv -9.28 0.40 0.02 -10.62 0.43 0.02 DELTA G solv 6.51 1.42 0.08 14.63 1.67 0.09
TOTAL 133.68 4.56 0.24 151.81 4.67 0.25 DELTA TOTAL -30.19 2.43 0.13 -32.09 2.38 0.13
(-)-Zuonin A pose 43 (+)-Zuonin A pose 46 (-)-Zuonin A pose 43 (+)-Zuonin A pose 46
Ligand (Zuonin A) Difference (Complex - Receptor - Ligand)




STable 14: Decomposition of (-)-zuonin A binding free energy contributions from 


























































































































































































































































































































































































































































































































































































































































































































































































































































STable 15: Decomposition of (-)-zuonin A binding free energy contributions from 


















































































































































































































































































































































































































































































































































































































































































































































































































































STable 16: Decomposition of (-)-zuonin A binding free energy contributions from 





















































































































































































































































































































































































































































































































































































































































































































































































































































SFigure 11: Stable binding pose of a) (-)-Zuonin A pose 43 and b) (+)-Zuonin A pose 39. 
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